Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Body adiposity index

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Body adiposity index. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-000223-85 Sponsor Protocol Number: 140631 Start Date*: 2015-04-09
    Sponsor Name:Örebro University Hospital
    Full Title: The effects of Vitamin D supplementation on cardiorespiratory fitness and adiposity in overweight men. A randomised, double-blind, placebo controlled study.
    Medical condition: We aim to examine the effects of Vitamin D supplementation on cardiorespiratory fitness and adiposity in overweight men.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003740-89 Sponsor Protocol Number: MR-Som-01-20 Start Date*: 2020-11-26
    Sponsor Name:SOCIETÀ ITALO BRITANNICA L. MANETTI - H. ROBERTS & C. PER AZIONI
    Full Title: A Phase IV, interventional, monocentric, not controlled study for the evaluation of new clinical and instrumental parameters on the efficacy of SOMATOLINE in the treatment of local adiposity and ce...
    Medical condition: local adiposity and cellulite
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10007882 Cellulitis PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003910-26 Sponsor Protocol Number: 01/2015 Start Date*: 2017-12-11
    Sponsor Name:Núcleo de Estudos de Hipertensão da Beira Interior
    Full Title: Fase II, unicenter, open, randomized trial to evaluate the response of Th17 and T regulatory lymphocytes to 24 weeks supplementation with cholecalciferol in patients with arterial hypertension, obe...
    Medical condition: Obesity associated arterial hypertension Metabolic syndrome associated arterial hypertension
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003320-40 Sponsor Protocol Number: EP-003 Start Date*: 2023-03-14
    Sponsor Name:Empros Pharma AB
    Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004415-37 Sponsor Protocol Number: NN8022-4179 Start Date*: 2015-11-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week dou...
    Medical condition: Obesity (Prader-Willi syndrome)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004366-14 Sponsor Protocol Number: MK-0364 012 Start Date*: 2006-11-13
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: Full title of the trial A Study to Assess the Efficacy and Tolerability of MK-0364 in Maintaining Weight Loss Induced by Diet in Obese Patients Followed by a 1-Year Extension
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003843-12 Sponsor Protocol Number: PP-CT01 Start Date*: 2017-01-16
    Sponsor Name:PILA PHARMA
    Full Title: A Single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in 24 patients with diabetes me...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002364-29 Sponsor Protocol Number: 015 Start Date*: 2005-09-02
    Sponsor Name:
    Full Title: A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001540-38 Sponsor Protocol Number: NN9536-4153 Start Date*: 2015-08-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, mul...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001049-24 Sponsor Protocol Number: NN8022-1839 Start Date*: 2008-12-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000204-11 Sponsor Protocol Number: NN9536-4578 Start Date*: 2021-01-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2006-002544-28 Sponsor Protocol Number: 0364-011 Start Date*: 2007-01-09
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM)
    Medical condition: Obesity in patients with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020458-33 Sponsor Protocol Number: GWMD1092 Start Date*: 2010-08-05
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in ...
    Medical condition: Dyslipidaemia in subjects with type 2 diabetes who have failed to achieve satisfactory lipid control with existing therapies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005084-26 Sponsor Protocol Number: A5351019 Start Date*: 2007-01-18
    Sponsor Name:Pfizer Inc
    Full Title: A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017080-41 Sponsor Protocol Number: GWMD09112 Start Date*: 2010-04-19
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.
    Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000907-13 Sponsor Protocol Number: 2007-24-001 Start Date*: 2007-11-13
    Sponsor Name:MUW, Innere Med III, Abt.für Endokrinologie & Stoffwechsel
    Full Title: The impact of Rimonabant in overweight women with prior gestational diabetes
    Medical condition: Rimonabant has been shown to reduce body weight and improve cardiovascular risk factors and metabolic control. Therefore we investigate in women with previous gestational diabetes and impaired glu...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033307 Overweight LLT
    9.1 10058110 Dyslipidemia LLT
    9.1 10051361 Adipositas LLT
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004353-14 Sponsor Protocol Number: NN8022-4180 Start Date*: 2016-08-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004430-96 Sponsor Protocol Number: 201600107 Start Date*: 2017-12-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk
    Medical condition: Testicular cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002199-88 Sponsor Protocol Number: NN8022-1922 Start Date*: 2008-12-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:10:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA